Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Hold” by Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned an average recommendation of “Hold” from the seventeen brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $172.31.

A number of research firms have commented on CRL. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Robert W. Baird boosted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, May 8th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Mizuho cut their price target on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 9th. Finally, TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price on the stock in a research note on Wednesday.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company’s stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 5,040 shares of company stock worth $807,407 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently added to or reduced their stakes in the company. Veracity Capital LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at $589,000. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock valued at $987,000 after acquiring an additional 1,679 shares in the last quarter. Boston Trust Walden Corp raised its holdings in Charles River Laboratories International by 4.3% in the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company’s stock valued at $37,748,000 after acquiring an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB raised its holdings in Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company’s stock valued at $480,000 after acquiring an additional 1,800 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $141.00 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $135.43 and its two-hundred day moving average is $164.86. The company has a market cap of $6.93 billion, a P/E ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.27 earnings per share. On average, equities analysts expect that Charles River Laboratories International will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).